- Home
- TSI vs VNDA Comparison
TSI vs VNDA Comparison
Compare TSI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- VNDA
- Stock Information
- Founded
- TSI 1987
- VNDA 2002
- Country
- TSI United States
- VNDA United States
- Employees
- TSI N/A
- VNDA N/A
- Industry
- TSI Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- VNDA Health Care
- Exchange
- TSI Nasdaq
- VNDA Nasdaq
- Market Cap
- TSI 234.6M
- VNDA 249.4M
- IPO Year
- TSI N/A
- VNDA 2006
- Fundamental
- Price
- TSI $4.91
- VNDA $4.36
- Analyst Decision
- TSI
- VNDA Strong Buy
- Analyst Count
- TSI 0
- VNDA 2
- Target Price
- TSI N/A
- VNDA $16.50
- AVG Volume (30 Days)
- TSI 106.8K
- VNDA 523.1K
- Earning Date
- TSI 01-01-0001
- VNDA 07-31-2025
- Dividend Yield
- TSI 7.46%
- VNDA N/A
- EPS Growth
- TSI N/A
- VNDA N/A
- EPS
- TSI N/A
- VNDA N/A
- Revenue
- TSI N/A
- VNDA $203,467,000.00
- Revenue This Year
- TSI N/A
- VNDA $16.86
- Revenue Next Year
- TSI N/A
- VNDA $39.78
- P/E Ratio
- TSI N/A
- VNDA N/A
- Revenue Growth
- TSI N/A
- VNDA 11.78
- 52 Week Low
- TSI $4.48
- VNDA $3.81
- 52 Week High
- TSI $4.87
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- TSI 48.56
- VNDA 44.63
- Support Level
- TSI $4.88
- VNDA $4.30
- Resistance Level
- TSI $4.96
- VNDA $4.47
- Average True Range (ATR)
- TSI 0.04
- VNDA 0.14
- MACD
- TSI -0.00
- VNDA 0.00
- Stochastic Oscillator
- TSI 50.10
- VNDA 29.33
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.